Welcome

Sign out Have a question? We're here to help

Copyright © 2019 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.

Kalvista Pharmaceuticals Inc (KALV)

$11.07 0.12 (1.10%)

16:00 EST KALV Stock Quote Delayed 15 Minutes

Volume:

Previous Close $11.07

Market Cap 119.51M

PE Ratio -24.07

EPS -0.46

Volume (Avg. Vol.) 77,000

Day's Range 10.84 - 11.22

52-Week Range 9.86 - 34.92

Dividend & Yield N/A (N/A)

KALV Stock Predictions, Articles, and Kalvista Pharmaceuticals Inc News

From InvestorPlace
From the Web

5 Stocks to Buy Based on Insider Buying

By Mark Putrino, CMT Oct 8, 2019

These are five stocks to consider buying because of significant insider buying activity. Insiders only buy for one reason: to make money.

Needham Remains a Buy on KalVista Pharmaceuticals Inc (KALV)

From Analyst Ratings Oct 25, 2019

In a report released today, Serge Belanger from Needham maintained a Buy rating on KalVista Pharmaceuticals Inc (KALV – Research Report), with a price target of $35.00. The company’s shares closed last Monday at $11.08, close to its 52-week low of $9.86. According to TipRanks.com, Belanger is a 1-star analyst with an average return of

KalVista Sees Hammer Chart Pattern: Time to Buy?

From Zacks Investment Research Oct 21, 2019

KalVista Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

Best & Worst Performing Small Cap Stocks for October 17, 2019

From StockNews.com Oct 17, 2019

PLX – PLX leads the way today as the best performing small cap stock, closing up 72.22%.

KalVista Pharmaceuticals Enters Oversold Territory

From Zacks Investment Research Oct 16, 2019

KalVista Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Stocks That Hit 52-Week Lows On Wednesday

From Benzinga Oct 9, 2019

On Wednesday morning, 192 companies achieved new lows for the year. Significant Points: The largest company by market cap to hit a new 52-week low was Personalis (NASDAQ: PSNL)....

The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug

From Benzinga Oct 9, 2019

The following is a roundup of top developments in the biotech space over the last 24 hours. None of the NYSE or Nasdaq-listed biotech stocks hit 52-week highs on...

Navellier Ratings

Powered by Portfolio Grader

Total Grade

D

Sell

Free Report

10 Stocks Set for Monster Growth

He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!

Download your FREE COPY!